Related Experiment Video

Updated: Jun 30, 2026

The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension
05:57

The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension

Published on: May 17, 2024

JTT-705: is there still future for a CETP inhibitor after torcetrapib?

Alexander J M Rennings1, Anton F H Stalenhoef

  • 1Radboud University Nijmegen Medical Centre, Department of Internal Medicine, 460, PO Box 9101, 6500 HB Nijmegen, The Netherlands. a.rennings@AIG.umcn.nl

Expert Opinion on Investigational Drugs
|September 24, 2008
PubMed

Insights

Cholesteryl ester transfer protein (CETP) inhibition aims to raise HDL cholesterol for treating atherosclerosis. Despite setbacks with torcetrapib, further CETP inhibitors like JTT-705 may still hold therapeutic potential.

Area of Science:

  • Cardiovascular Pharmacology
  • Lipid Metabolism Research
  • Atherosclerosis Therapeutics

Background:

  • Residual atherosclerosis risk persists despite low-density lipoprotein cholesterol reduction.
  • Increasing high-density lipoprotein (HDL) cholesterol is a proposed antiatherogenic strategy.
  • Cholesteryl ester transfer protein (CETP) inhibition is a method to raise HDL cholesterol.

Purpose of the Study:

  • To evaluate the potential of CETP inhibition with JTT-705 following the failure of torcetrapib in Phase III trials.
  • To assess the future prospects of CETP inhibitors in light of clinical trial outcomes.

Main Methods:

  • Literature search of PubMed.
  • Inclusion of articles citing JTT-705, torcetrapib, and anacetrapib.
  • Focus on studies related to pharmacological HDL-cholesterol raising and CETP inhibition.

Main Results:

  • The failure of torcetrapib raises questions about the efficacy of CETP inhibitors.
  • Evidence suggests a potential role for HDL-cholesterol raising therapies.

Conclusions:

  • Further Phase III clinical studies are required for JTT-705 and anacetrapib.
  • The therapeutic benefit of CETP inhibition remains to be definitively determined.
Abstract

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...